학술논문
CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets
Document Type
Academic Journal
Source
Genome Biology (Online Edition). August 19, 2020, Vol. 21 Issue 1
Subject
Language
English
Abstract
Author(s): Imran Noorani[sup.1,2,3], Allan Bradley[sup.1] and Jorge de la Rosa[sup.1] Introduction Large-scale human tumor sequencing projects have been invaluable in establishing the genetic landscapes of many cancers [1]. These have [...]
Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of 'passenger' changes still remains a major challenge. Transposon and CRISPR screens in vivo provide complementary methods for achieving this, and each platform has its own advantages. Here, we review recent major technological breakthroughs made with these two approaches and highlight future directions. We discuss how each genetic screening platform can provide unique insight into cancer evolution, including intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities for targeted therapeutic intervention.
Human cancers harbor substantial genetic, epigenetic, and transcriptional changes, only some of which drive oncogenesis at certain times during cancer evolution. Identifying the cancer-driver alterations amongst the vast swathes of 'passenger' changes still remains a major challenge. Transposon and CRISPR screens in vivo provide complementary methods for achieving this, and each platform has its own advantages. Here, we review recent major technological breakthroughs made with these two approaches and highlight future directions. We discuss how each genetic screening platform can provide unique insight into cancer evolution, including intra-tumoral heterogeneity, metastasis, and immune evasion, presenting transformative opportunities for targeted therapeutic intervention.